Reptides

The peptide industry is a sales floor... Affiliate codes, influencer hype, vendors selling, doctors selling. All peptide information right now is a marketing funnel. Reptides is the evidence layer. And for $100 you get unlimited access, for a lifetime. To an ever evolving research platform.

Who’s gonna tell him?

If you think the grey-market peptide hype was big Just wait until they make it to the open market

hhs just said it won't go after licensed pharmacies that make these 6 peptides: bpc-157, tb-500, kpv, mots-c, epitalon, semax you still need a prescription. it's not fda approval. the reason they gave: get people off overseas research-only peptides. if anything this signals a prolonged bull market for RUO.

$LLY's experimental eloralintide + tirzepatide: up to 23.3% estimated average weight loss vs 14.8% with tirzepatide 15 mg at 48 weeks in Phase 2b type 2 diabetes data. Side-effect dropouts: 10.8–27% across combo groups vs 2.9% on tirzepatide.

BREAKING: OIRA completed its review of FDA's interim peptide compounding policy on Oct. 27: "Consistent with Change." A meaningful step toward potential pharmacy access.

$LLY reports estimated average weight loss of 19.5–20.9% with retatrutide vs 9.4% with $NVO's Ozempic 2 mg at 80 weeks in a Phase 3 type 2 diabetes trial.

$GILD just agreed to pay $1.275 billion upfront for an oral peptide program. According to Gilead, the deal with PepStar Therapeutics includes HCXT-2001, an experimental macrocyclic peptide that blocks the IL-23 receptor, a target involved in inflammatory diseases. Gilead sees potential to develop it as a daily pill for inflammatory bowel disease, either on its own or combined with another drug in its pipeline, emvistegrast. Psoriasis is another potential application. The candidate is still in Phase 1, with safety and efficacy yet to be established. The acquisition is expected to close in Q4 2026.

Scientists designed a peptide to fight Alzheimer's According to a new study in PNAS Nexus, researchers developing HAEE, a four-amino-acid peptide designed to interfere with amyloid buildup, detected a naturally occurring version in all 150 healthy participants tested. Average blood levels were roughly 50% lower in 200 people clinically diagnosed with Alzheimer's. The finding opens up two potential research paths: using HAEE levels as a blood biomarker and investigating the peptide as a treatment candidate. This was a blood-sample study, so whether administering HAEE actually helps people with Alzheimer's remains unproven.

GH / growth: 6 new compounds on reptides B: Anamorelin C: Capromorelin, Hexarelin D: ACE-031, PEG-MGF F: IGF-1 DES

Skin / cosmetic: 8 new compounds on reptides S: Isotretinoin (Accutane) A: Clascoterone, Ketoconazole C: PDRN, PP405, Pyrilutamide, Topilutamide (fluridil) D: Dalosirvat

Androgens / anabolics: 10 new compounds on reptides B: Fluoxymesterone C: GSK-2881078 D: AC-262536, ACP-105, Andarine, S-23 F: Dihydroboldenone (1-testosterone), Methasterone, Mibolerone, Turinabol

Sexual / hormonal: 14 new compounds on reptides S: Sildenafil A: Anastrozole, Cabergoline, Exemestane, Letrozole, Mirodenafil, Raloxifene, Tamoxifen B: DHEA C: Afimoxifene, Endoxifen D: Ovagen, Prostamax, Testagen

Healing / tissue: 26 new compounds on reptides S: Eplerenone, Ezetimibe, Hydrochlorothiazide, Rosuvastatin, Teriparatide A: Empagliflozin, Low-dose naltrexone, N-acetylcysteine, Roxadustat, Spironolactone B: Coenzyme Q10, Meldonium C: B7-33, Bronchogen, Cardiogen, Livagen, LL-37, Magnesium glycinate, Pancragen, PNC-27, Retinalamin, Thymogen, Thymulin, TUDCA D: Chonluten F: Fenbendazole

Weight loss: 42 new compounds on reptides S: Dulaglutide, Orlistat, Phentermine A: Ecnoglutide, Exenatide, Ketotifen, Mirabegron, Pramlintide, Setmelanotide, Sitagliptin B: Aleniglipron, Amlexanox, Amycretin, Elecoglipron, Maridebart cafraglutide, Pemvidutide, Petrelintide, Ribupatide, Safiglipron, Trevogrumab, UBT251, VK2735 C: ACCG-2671, AZD6234, Berberine, Berobenatide, Efinopegdutide, Enicepatide, GUBamy, JBSNF-000088, KAI-4729, MET-233, SAR441255, Sobetirome, Yohimbine D: 3,5-diiodo-L-thyronine (T2), Adipotide, AICAR, CL-316243, DADA, Dapiglutide, SR-9009

A new Scientific Reports paper studied MOTS-c in mice with diabetes and metabolic fatty liver disease, alongside laboratory liver-cell experiments. Both aerobic exercise and administered MOTS-c reduced liver fat accumulation and inflammatory markers.

BREAKING: Hims & Hers is scheduled to meet with White House Office of Management and Budget (OMB) and Office of Information and Regulatory Affairs (OIRA) budget officials TOMORROW (Friday, October 23, 2026) to discuss the FDA's proposed interim peptide access policy.

Nootropic / longevity: 51 new compounds on reptides A: Clonidine, Oveporexton, Propranolol, Tranylcypromine, Trazodone, Tropisetron, Zopiclone B: Agomelatine, Methylcobalamin C: ACD856, Bemethyl, BPAP, Calcium alpha-ketoglutarate, CE-123, Citicoline, CMS-121, Cortagen, Dasatinib plus quercetin, DNSP-11, Emoxypine succinate, FGL peptide, Fisetin, FOXO4-DRI, GB-115 (Ranquilon), Hydromethylthionine, ISRIB, L-tetrahydropalmatine, Lithium orotate, Nicotinamide riboside, Nooglutyl, Osavampator, P021, PPAP, Sipagladenant, Spermidine, Taurine, TND1128, Urolithin A D: 7,8-Dihydroxyflavone, 9-Me-BC, Cortexin, Crystagen, NSI-189 phosphate, Picamilon, PRL-8-53, Sunifiram, Thozalinone, Unifiram F: Phenibut, RGPU-95, Tianeptine